psalexa
logo

Hemodynamic Monitoring Systems Market

Global Hemodynamic Monitoring Systems Market Size, Share, Development, Growth and Demand Forecast to 2023

Delivery : 24-72 Working Hours
Report Code: LS10416
Available Format:

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline analysis by phase

1.3.2 Pipeline analysis by route of administration

1.3.3 Pipeline analysis by molecule type

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of primary research respondents

2.2.1.1 By industry participant

2.2.1.2 By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Overview

4.2 Key Drivers

4.2.1 Novel therapies in hemophilia pipeline

4.2.2 Technical advancements

4.3 Key Barriers

4.3.1 Lack of awareness about medication for the treatment of hemophilia

4.3.2 Less number of treatment options

4.4 Hemophilia Pipeline Analysis

4.4.1 Pipeline analysis by phase

4.4.2 Pipeline analysis by molecule type

4.4.3 Pipeline analysis by route of administration

4.4.4 Pipeline analysis by company

Chapter 5. Hemophilia Pipeline Analysis by Phase (2017)

5.1 Filed

5.1.1 LR-769

5.1.1.1 Clinical trials

5.1.1.2 Clinical trial results

5.1.1.3 Strategic development

5.1.1.4 Technology

5.2 Phase III

5.2.1 Emicizumab

5.2.1.1 Clinical trials

5.2.1.2 Clinical trial results

5.2.1.3 Strategic development

5.2.1.4 Designation

5.2.1.5 Technology

5.2.2 NN7088

5.2.2.1 Clinical trials

5.2.2.2 Clinical trial results

5.2.2.3 Strategic development

5.2.2.4 Technology

5.2.3 Damoctocog alfa pegol

5.2.3.1 Clinical trials

5.3 Phase II

5.3.1 Fitusiran

5.3.1.1 Clinical trials

5.3.1.2 Clinical trial results

5.3.1.3 Strategic development

5.3.2 PF-06838435

5.3.2.1 Clinical trials

5.3.2.2 Strategic development

5.3.2.3 Designation

5.3.2.4 Technology

5.3.3 CSL689 rVIIa-FP

5.3.3.1 Pre-Clinical studies

5.3.3.2 Clinical trials

5.3.3.3 Clinical trial results

5.3.3.4 Designation

5.3.4 PF-06741086

5.3.4.1 Clinical trials

5.3.4.2 Clinical trial results

5.3.4.3 Designation

5.4 Phase I

5.4.1 SHP656

5.4.1.1 Clinical trials

5.4.1.2 Clinical results

5.4.1.3 Strategic development

5.4.1.4 Technology

5.4.2 BAY1093884

5.4.2.1 Clinical trials

5.4.2.2 Clinical trial results

5.4.3 Concizumab

5.4.3.1 Pre-Clinical studies

5.4.3.2 Clinical trials

5.4.4 Marzeptacog alfa (activated)

5.4.4.1 Clinical trials

5.4.4.2 Clinical trial results

5.4.4.3 Strategic development

5.4.4.4 Designation

5.4.5 ATX-F8117

5.4.5.1 Designation

5.4.6 BMN-270

5.4.6.1 Pre-Clinical studies

5.4.6.2 Clinical trials

5.4.6.3 Clinical trial results

5.4.6.4 Designation

5.4.7 NN7170

5.4.7.1 Clinical trials

5.4.7.2 Strategic development

5.4.7.3 Technology

5.4.8 SB-525 cDNA gene therapy

5.4.8.1 Clinical trials

5.4.8.2 Strategic development

5.4.8.3 Designation

5.4.9 SB-FIX

5.4.9.1 Pre-Clinical studies

5.4.9.2 Clinical trials

5.4.9.3 Technology

5.4.9.4 Designation

5.4.10 SPK-8011

5.4.10.1 Clinical trials

5.4.10.2 Technology

5.4.11 Factor IX

5.4.11.1 Pre-Clinical studies

5.4.12 AMT-060

5.4.12.1 Clinical trials

5.4.12.2 Clinical trial results

5.4.12.3 Strategic development

5.4.12.4 Technology

5.4.12.5 Designation

5.5 Pre-Clinical

5.6 Discovery

Chapter 6. Competitive Landscape

6.1 Key Players Benchmarking for Hemophilia Drug Pipeline

6.2 SWOT Analysis of Hemophilia Pipeline

Chapter 7. Company Profiles

7.1 F. Hoffmann-La Roche Ltd.

7.1.1 Business overview

7.1.2 Product and service offerings

7.2 Pfizer Inc.

7.2.1 Business overview

7.2.2 Product and service offerings

7.3 Bayer, AG

7.3.1 Business overview

7.3.2 Product and service offerings

7.4 Spark Therapeutics, Inc.

7.4.1 Business overview

7.4.2 Product and service offerings

7.5 Catalyst Biosciences, Inc.

7.5.1 Business overview

7.5.2 Product and service offerings

7.6 Alnylam Pharmaceuticals, Inc.

7.6.1 Business overview

7.6.2 Product and service offerings

7.7 Sangamo BioSciences, Inc.

7.7.1 Business overview

7.7.2 Product and service offerings

7.8 Dimension Therapeutics, Inc.

7.8.1 Business overview

7.8.2 Product and service offerings

7.9 uniQure N.V.

7.9.1 Business overview

7.9.2 Product and service offerings

Chapter 8. Appendix

8.1 Abbreviations

 

List of Tables

TABLE 1: PIPELINE ANALYSIS OF HEMOPHILIA, BY COMPANY (2017)

TABLE 2: DESCRIPTION OF LR-769

TABLE 3: CLINICAL TRIALS OF LR-769

TABLE 4: DESCRIPTION OF EMICIZUMAB

TABLE 5: CLINICAL TRIALS OF EMICIZUMAB

TABLE 6: DESCRIPTION OF NN7088

TABLE 7: CLINICAL TRIALS OF NN7088

TABLE 8: DESCRIPTION OF DAMOCTOCOG ALFA PEGOL

TABLE 9: CLINICAL TRIALS OF DAMOCTOCOG ALFA PEGOL

TABLE 10: DESCRIPTION OF FITUSIRAN

TABLE 11: CLINICAL TRIALS OF ALN-AT3SC

TABLE 12: DESCRIPTION OF PF-06838435

TABLE 13: CLINICAL TRIALS OF PF-06838435

TABLE 14: DESCRIPTION OF CSL689 RVIIA-FP

TABLE 15: CLINICAL TRIALS OF CSL689

TABLE 16: DESCRIPTION OF PF-06741086

TABLE 17: CLINICAL TRIALS OF PF-06741086

TABLE 18: DESCRIPTION OF SHP656

TABLE 19: CLINICAL TRIALS OF SHP656

TABLE 20: DESCRIPTION OF BAY1093884

TABLE 21: CLINICAL TRIALS OF BAY1093884

TABLE 22: DESCRIPTION OF CONCIZUMAB

TABLE 23: CLINICAL TRIALS OF CONCIZUMAB

TABLE 24: DESCRIPTION OF MARZEPTACOG ALFA (ACTIVATED)

TABLE 25: CLINICAL TRIALS OF MARZEPTACOG ALFA (ACTIVATED)

TABLE 26: DESCRIPTION OF ATX-F8117

TABLE 27: DESCRIPTION OF BMN-270

TABLE 28: CLINICAL TRIALS OF BMN-270

TABLE 29: DESCRIPTION OF NN7170

TABLE 30: CLINICAL TRIALS OF NN7170

TABLE 31: DESCRIPTION OF SB-525 CDNA GENE THERAPY

TABLE 32: CLINICAL TRIALS OF SB-525 CDNA GENE THERAPY

TABLE 33: DESCRIPTION OF SB-FIX

TABLE 34: CLINICAL TRIALS OF SB-FIX

TABLE 35: DESCRIPTION OF SPK-8011

TABLE 36: CLINICAL TRIALS OF SPK-8011

TABLE 37: DESCRIPTION OF FACTOR IX

TABLE 38: DESCRIPTION OF AMT-060

TABLE 39: CLINICAL TRIALS OF AMT-060

TABLE 40: F. HOFFMANN-LA ROCHE LTD. – AT A GLANCE

TABLE 41: PFIZER INC. – AT A GLANCE

TABLE 42: BAYER AG – AT A GLANCE

TABLE 43: SPARK THERAPEUTICS, INC. – AT A GLANCE

TABLE 44: CATALYST BIOSCIENCES, INC. – AT A GLANCE

TABLE 45: ALNYLAM PHARMACEUTICALS, INC. – AT A GLANCE

TABLE 46: SANGAMO BIOSCIENCES, INC. – AT A GLANCE

TABLE 47: DIMENSION THERAPEUTICS, INC. – AT A GLANCE

TABLE 48: UNIQURE N.V. – AT A GLANCE

 

List of Figures

 

FIG 1: RESEARCH METHODOLOGY FOR THE HEMOPHILIA PIPELINE ANALYSIS

FIG 2: SPLIT OF PRIMARY AND SECONDARY RESEARCH

FIG 3: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT

FIG 4: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE

FIG 5: ROLE OF CLOTTING FCATORS IN COAGUALTION

FIG 6: NUMBER OF HEMOPHILIA DRUG CANDIDATES UNDER DEVELOPMENT (2017)

FIG 7: HEMOPHILIA PIPELINE SPLIT, BY MOLECULE TYPE (2017)

FIG 8: HEMOPHILIA PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)

FIG 9: KEY PLAYERS BENCHMARKING FOR HEMOPHILIA DRUG PIPELINE

FIG 10: SWOT ANALYSIS OF HEMOPHILIA PIPELINE 

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 5100
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 6100
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 9100

Pre-Purchase Enquiry